| Nov 13 |
FibroBiologics reports 9M results
|
| Nov 12 |
FibroBiologics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
|
| Oct 29 |
FibroBiologics Announces Updates for Novel Artificial Thymus Organoid Technology
|
| Oct 28 |
FibroBiologics to Present at the 2024 ThinkEquity Conference and BIO-Europe 2024
|
| Oct 21 |
FibroBiologics and Charles River link for chronic disease therapies manufacture
|
| Oct 16 |
FibroBiologics Issued Patent for Fibroblast Delivery of Tumor Inhibitory Agents by the European Patent Office
|
| Oct 11 |
FibroBiologics to Participate in a Fireside Chat at 2024 Maxim Healthcare Virtual Summit
|
| Sep 30 |
FibroBiologics to Present at 2024 Cell & Gene Meeting on the Mesa
|
| Sep 19 |
FibroBiologics Engages Southern Star Research as CRO in Australia
|
| Sep 12 |
FibroBiologics Announces Filing of Patent Application for Generation of Three-dimensional Organoids using Fibroblast Cell-Based Technology
|
